Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Abhishek Maiti, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objective: -To evaluate Safety of the combination of azacitidine, venetoclax and allogeneic NK cells Secondary Objective: * To estimate overall response rate (ORR) * To estimate rate of CR/CRi by 4 cycles of therapy * To estimate rate of MRD negative by 6 cycles * To estimate overall survival (OS) * To estimate relapse-free survival (RFS) Exploratory Objectives: * To estimate rate of CRc MRD negative at any time * To estimate event-free survival (EFS) * To estimate duration of response (DOR) * To estimate median time to blood count recovery * To estimate median time to first response * To estimate median time to negative MRD * To evaluate persistence of NK cells in peripheral blood * To explore biomarker of response and resistance * Using propensity-score matching analysis (per post-hoc plan) to explore the difference in response, survival adverse events in contemporary historical control population treated with HMA-VEN
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted